查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1701333

罕見疾病臨床檢測市場規模、佔有率、趨勢分析報告：按階段、治療領域、贊助商、地區和細分市場預測，2025 年至 2030 年

Rare Disease Clinical Trials Market Size, Share, & Trends Analysis Report By Phase (Phase I, Phase II, Phase III, Phase IV), By Therapeutic Area (Oncology, Cardiovascular), By Sponsor, By Region, And Segment Forecasts, 2025 - 2030
出版日期: | 出版商: Grand View Research | 英文 100 Pages | 商品交期: 2-10個工作天內

價格

罕見疾病臨床檢測市場的成長與趨勢

根據 Grand View Research, Inc. 的最新報告，全球罕見疾病臨床檢測市場預計到 2030 年將達到 190.2 億美元，2025 年至 2030 年期間的複合年成長率為 6.8%。

罕見疾病臨床檢測產業的主要驅動力是全球罕見疾病的沉重負擔和日益成長的研究需求。此外，間歇性的產品發布和大量正在籌備的產品也推動了成長。政府鼓勵產品開發的措施（例如《孤兒藥法案》）預計將進一步促進該產業的發展。

根據美國國立衛生研究院（NIH）的數據，全球有超過7000種罕見疾病。這些疾病影響了約 3000 萬美國人，即十分之一的美國人。據 Eurodis 稱，72% 的罕見疾病是遺傳性的，其餘則是感染疾病、過敏性或環境性的。人們對罕見疾病的認知不斷提高，對開發治療罕見疾病的潛在治療方法的興趣日益濃厚，預計將支持市場的成長。

製藥公司和非營利組織正在積極資助罕見疾病臨床研究。例如，2022年2月，衛生研究委員會提供了110萬美元的資金，用於支持罕見疾病臨床測試。預計未來將繼續進行類似的努力，在預測期內為市場提供支援。

近年來，孤兒藥的銷售額穩定成長。例如，根據Evaluate Pharma的數據，孤兒藥銷售額將在2020年達到1,380億美元，並在2022年達到1,720億美元。預計到2026年孤兒藥銷售額將達2,680億美元。罕見疾病治療藥物銷售額的成長預計將激發研究人員對開發該領域新療法的興趣，從而為疫情後的市場提供支持。

罕見疾病臨床檢測市場報告重點

  • 到 2024 年，III 期臨床試驗部分將佔據市場主導地位，收入佔有率將達到 54.2%。由於需要大量志願者，III 期罕見疾病臨床試驗成本高昂，推動了這一部分的成長。
  • 2024年，腫瘤學將佔據銷售額的最大佔有率。研究人員對開發治療罕見癌症的新潛在治療方法的興趣日益濃厚，這推動了這一領域的成長。
  • 由於非營利組織提供大量資金支持罕見疾病臨床研究，預計預測期內非營利組織部門將以顯著的複合年成長率成長。
  • 到2024年，北美將佔據市場主導地位，銷售額佔比達42.6%。北美罕見疾病發生率高以及臨床檢測領域公司數量眾多是其市場佔有率高的主要原因。

目錄

第1章調查方法與範圍

第2章執行摘要

3. 罕見疾病臨床檢測市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析

第4章罕見疾病臨床檢測市場：階段業務分析

  • 2024年及2030年的階段市場佔有率
  • 階段細分儀表板
  • 市場規模、預測與趨勢分析（分階段，2018-2030年）
  • 第一階段
  • 第二階段
  • 第三階段
  • 第四階段

第5章罕見疾病臨床測試市場：治療領域商業分析

  • 2024 年和 2030 年治療領域市場佔有率
  • 治療領域細分儀表板
  • 按治療領域分類的市場規模、預測和趨勢分析（2018-2030 年）
  • 腫瘤學
  • 心血管疾病
  • 神經系統疾病
  • 感染疾病
  • 遺傳性疾病
  • 自體免疫和炎症
  • 血液系統疾病
  • 肌肉骨骼疾病
  • 其他

第6章 罕見疾病臨床試驗市場：申辦方業務分析

  • 2024年和2030年的贊助市場佔有率
  • 贊助細分儀表板
  • 市場規模、預測和趨勢分析（按贊助商，2018-2030 年）
  • 製藥和生物製藥公司
  • 非營利組織
  • 其他

第7章：罕見疾病臨床檢測市場：按地區估計和趨勢分析

  • 2024 年及 2030 年區域市場佔有率分析
  • 區域市場儀表板
  • 2018-2030年市場規模及預測趨勢分析
  • 北美洲
    • 2018-2030年各國情況
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 2018-2030年各國情況
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 韓國
    • 澳洲
    • 泰國
  • 拉丁美洲
    • 2018-2030年各國情況
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 2018-2030年各國情況
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章競爭格局

  • 參與者概述
  • 企業市場分析
  • 公司分類
  • 戰略地圖
  • 公司簡介/上市公司
    • Takeda Pharmaceutical Company Limited
    • F. Hoffmann-La Roche Ltd
    • Pfizer Inc
    • AstraZeneca
    • Novartis AG
    • Laboratory Corporation of America Holdings（LabCorp）
    • IQVIA
    • Charles River Laboratories
    • ICON plc
    • Parexel International（MA）Corporation
Product Code: GVR-4-68040-031-1

Rare Disease Clinical Trials Market Growth & Trends:

The global rare disease clinical trials market size is expected to reach USD 19.02 billion by 2030, expanding at 6.8% CAGR from 2025 to 2030, according to a new report by Grand View Research, Inc. The main driving factors of the rare disease clinical trial industry are the high burden of rare diseases worldwide, which has led to rising demand for research. Furthermore, intermittent launches and a large number of products in the pipeline also propel growth. Government initiatives that encourage product development, such as the Orphan Drug Act, are further expected to assist industry growth.

According to the National Institutes of Health (NIH), there are more than 7,000 rare diseases worldwide. These diseases affect nearly 30 million Americans, or 1 in every 10 people. Eurodis states that 72% of rare diseases are genetic, while others are caused by infections, allergies, and environmental causes. The growing awareness among people regarding rare diseases and growing interest in developing potential treatments for treating rare diseases are expected to support market growth.

Pharmaceutical companies and non-profit organizations are actively providing funding for rare disease clinical research. For instance, in February 2022, the Health Research Board funded USD 1.1 million to support rare disease clinical trials. Similar initiatives in the future are expected to support the market during the forecast period.

Orphan drug sales have been steadily increasing in recent years. For instance, according to Evaluate Pharma, orphan drug sales accounted for USD 138 billion in 2020, and by 2022, they accounted for USD 172 billion. It is estimated that orphan drug sales will reach USD 268 billion by 2026. The rise in the sales of orphan drugs is expected to generate interest among researchers in developing new treatments in the area of rare diseases and thus support the market in the post-pandemic period.

Rare Disease Clinical Trials Market Report Highlights:

  • The phase III segment dominated the market with the largest revenue share of 54.2% in 2024. The segment's growth is supported by the high cost of phase III rare disease clinical trials due to the requirement for a large number of volunteers
  • The oncology segment dominated the market with the largest revenue share in 2024. The growing interest of researchers in the development of new potential treatments for treating rare cancers is supporting the growth of the segment
  • The non-profit organizations segment is projected to grow at a significant CAGR over the forecast period owing to the significant funding offered by these organizations to support rare disease clinical research
  • North America dominated the market and accounted for a revenue share of 42.6% in 2024. The high burden of rare diseases in North America and the presence of a large number of players in clinical trials are some of the key reasons for its high market share

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Phase
    • 1.2.2. Therapeutic Area
    • 1.2.3. Sponsor
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Rare Disease Clinical Trials Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis

Chapter 4. Rare Disease Clinical Trials Market: Phase Business Analysis

  • 4.1. Phase Market Share, 2024 & 2030
  • 4.2. Phase Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Phase, 2018 to 2030 (USD Billion)
  • 4.4. Phase I
    • 4.4.1. Phase I Market, 2018 - 2030 (USD Billion)
  • 4.5. Phase II
    • 4.5.1. Phase II Market, 2018 - 2030 (USD Billion)
  • 4.6. Phase III
    • 4.6.1. Phase II Market, 2018 - 2030 (USD Billion)
  • 4.7. Phase IV
    • 4.7.1. Phase IV Market, 2018 - 2030 (USD Billion)

Chapter 5. Rare Disease Clinical Trials Market: Therapeutic Area Business Analysis

  • 5.1. Therapeutic Area Market Share, 2024 & 2030
  • 5.2. Therapeutic Area Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Therapeutic Area, 2018 to 2030 (USD Billion)
  • 5.4. Oncology
    • 5.4.1. Oncology Market, 2018 - 2030 (USD Billion)
  • 5.5. Cardiovascular Disorders
    • 5.5.1. Cardiovascular Disorders Market, 2018 - 2030 (USD Billion)
  • 5.6. Neurological Disorders
    • 5.6.1. Neurological Disorders Market, 2018 - 2030 (USD Billion)
  • 5.7. Infectious Disease
    • 5.7.1. Infectious Disease Market, 2018 - 2030 (USD Billion)
  • 5.8. Genetic Disorders
    • 5.8.1. Genetic Disorders Market, 2018 - 2030 (USD Billion)
  • 5.9. Autoimmune and Inflammation
    • 5.9.1. Autoimmune and Inflammation Market, 2018 - 2030 (USD Billion)
  • 5.10. Hematologic Disorders
    • 5.10.1. Hematologic Disorders Market, 2018 - 2030 (USD Billion)
  • 5.11. Musculoskeletal Disorders
    • 5.11.1. Musculoskeletal Disorders Market, 2018 - 2030 (USD Billion)
  • 5.12. Others
    • 5.12.1. Others Market, 2018 - 2030 (USD Billion)

Chapter 6. Rare Disease Clinical Trials Market: Sponsor Business Analysis

  • 6.1. Sponsor Market Share, 2024 & 2030
  • 6.2. Sponsor Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by Sponsor, 2018 to 2030 (USD Billion)
  • 6.4. Pharmaceutical & Biopharmaceutical Companies
    • 6.4.1. Pharmaceutical & Biopharmaceutical Companies Market, 2018 - 2030 (USD Billion)
  • 6.5. Non-Profit Organizations
    • 6.5.1. Non-Profit Organizations Market, 2018 - 2030 (USD Billion)
  • 6.6. Other
    • 6.6.1. Other Market, 2018 - 2030 (USD Billion)

Chapter 7. Rare Disease Clinical Trials Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2030
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2018 to 2030:
  • 7.4. North America
    • 7.4.1. North America Rare Disease Clinical Trials Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Regulatory Framework
      • 7.4.2.3. Competitive Insights
      • 7.4.2.4. U.S. Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Regulatory Framework
      • 7.4.3.3. Competitive Insights
      • 7.4.3.4. Canada Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Regulatory Framework
      • 7.4.4.3. Competitive Insights
      • 7.4.4.4. Mexico Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Rare Disease Clinical Trials Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Regulatory Framework
      • 7.5.2.3. Competitive Insights
      • 7.5.2.4. UK Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Regulatory Framework
      • 7.5.3.3. Competitive Insights
      • 7.5.3.4. Germany Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Regulatory Framework
      • 7.5.4.3. Competitive Insights
      • 7.5.4.4. France Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Regulatory Framework
      • 7.5.5.3. Competitive Insights
      • 7.5.5.4. Italy Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Regulatory Framework
      • 7.5.6.3. Competitive Insights
      • 7.5.6.4. Spain Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Regulatory Framework
      • 7.5.7.3. Competitive Insights
      • 7.5.7.4. Denmark Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Regulatory Framework
      • 7.5.8.3. Competitive Insights
      • 7.5.8.4. Sweden Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Regulatory Framework
      • 7.5.9.3. Competitive Insights
      • 7.5.9.4. Norway Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Regulatory Framework
      • 7.6.2.3. Competitive Insights
      • 7.6.2.4. Japan Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Regulatory Framework
      • 7.6.3.3. Competitive Insights
      • 7.6.3.4. China Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Regulatory Framework
      • 7.6.4.3. Competitive Insights
      • 7.6.4.4. India Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.5. South Korea
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Regulatory Framework
      • 7.6.5.3. Competitive Insights
      • 7.6.5.4. South Korea Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.6. Australia
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Regulatory Framework
      • 7.6.6.3. Competitive Insights
      • 7.6.6.4. Australia Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Regulatory Framework
      • 7.6.7.3. Competitive Insights
      • 7.6.7.4. Thailand Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Rare Disease Clinical Trials Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Regulatory Framework
      • 7.7.2.3. Competitive Insights
      • 7.7.2.4. Brazil Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Regulatory Framework
      • 7.7.3.3. Competitive Insights
      • 7.7.3.4. Argentina Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
  • 7.8. MEA
    • 7.8.1. MEA Rare Disease Clinical Trials Market Estimates and Forecasts, by Country, 2018 - 2030 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Regulatory Framework
      • 7.8.2.3. Competitive Insights
      • 7.8.2.4. South Africa Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Regulatory Framework
      • 7.8.3.3. Competitive Insights
      • 7.8.3.4. Saudi Arabia Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Regulatory Framework
      • 7.8.4.3. Competitive Insights
      • 7.8.4.4. UAE Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Regulatory Framework
      • 7.8.5.3. Competitive Insights
      • 7.8.5.4. Kuwait Rare Disease Clinical Trials Market Estimates and Forecasts, 2018 - 2030 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Takeda Pharmaceutical Company Limited
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. F. Hoffmann-La Roche Ltd
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Pfizer Inc
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. AstraZeneca
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Novartis AG
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Laboratory Corporation of America Holdings (LabCorp)
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. IQVIA
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Charles River Laboratories
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. ICON plc
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Parexel International (MA) Corporation
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives

List of Tables

  • Table 1. List of secondary sources
  • Table 2. List of abbreviations
  • Table 3. Global rare disease clinical trials market, by region, 2018 - 2030 (USD Billion)
  • Table 4. Global rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 5. Global rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 6. Global rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 7. North America rare disease clinical trials market, by country, 2018 - 2030 (USD Billion)
  • Table 8. North America rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 9. North America rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 10. North America rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 11. U.S. rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 12. U.S. rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 13. U.S. rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 14. Canada rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 15. Canada rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 16. Canada rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 17. Mexico rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 18. Mexico rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 19. Mexico rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 20. Europe rare disease clinical trials market, by country, 2018 - 2030 (USD Billion)
  • Table 21. Europe rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 22. Europe rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 23. Europe rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 24. UK rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 25. UK rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 26. UK rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 27. Germany rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 28. Germany rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 29. Germany rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 30. France rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 31. France rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 32. France rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 33. Italy rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 34. Italy rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 35. Italy rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 36. Spain rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 37. Spain rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 38. Spain rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 39. Denmark rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 40. Denmark rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 41. Denmark rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 42. Sweden rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 43. Sweden rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 44. Sweden rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 45. Norway rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 46. Norway rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 47. Norway rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 48. Asia Pacific rare disease clinical trials market, by country, 2018 - 2030 (USD Billion)
  • Table 49. Asia Pacific rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 50. Asia Pacific rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 51. Asia Pacific rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 52. Japan rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 53. Japan rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 54. Japan rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 55. China rare disease clinical trials market, by phase, 2018-2030 (USD Billion)
  • Table 56. China rare disease clinical trials market, by therapeutic area, 2018-2030 (USD Billion)
  • Table 57. China rare disease clinical trials market, by sponsor, 2018-2030 (USD Billion)
  • Table 58. India rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 59. India rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 60. India rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 61. South Korea rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 62. South Korea rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 63. South Korea rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 64. Australia rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 65. Australia rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 66. Australia rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 67. Thailand rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 68. Thailand rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 69. Thailand rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 70. Latin America rare disease clinical trials market, by country, 2018 - 2030 (USD Billion)
  • Table 71. Latin America rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 72. Latin America rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion
  • Table 73. Latin America rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion
  • Table 74. Brazil rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 75. Brazil rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 76. Brazil rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 77. Argentina rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 78. Argentina rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 79. Argentina rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 80. Middle East & Africa rare disease clinical trials market, by country, 2018 - 2030 (USD Billion)
  • Table 81. Middle East & Africa rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 82. Middle East & Africa rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 83. Middle East & Africa rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 84. South Africa rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 85. South Africa rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 86. South Africa rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 87. Saudi Arabia rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 88. Saudi Arabia rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 89. Saudi Arabia rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 90. UAE rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 91. UAE rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 92. UAE rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)
  • Table 93. Kuwait rare disease clinical trials market, by phase, 2018 - 2030 (USD Billion)
  • Table 94. Kuwait rare disease clinical trials market, by therapeutic area, 2018 - 2030 (USD Billion)
  • Table 95. Kuwait rare disease clinical trials market, by sponsor, 2018 - 2030 (USD Billion)

List of Figures

  • Fig. 1 Rare disease clinical trials market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Phase outlook (USD Billion)
  • Fig. 10 Therapeutic area outlook (USD Billion)
  • Fig. 11 Sponsor outlook (USD Billion)
  • Fig. 12 Competitive landscape
  • Fig. 13 Rare disease clinical trials market dynamics
  • Fig. 14 Rare disease clinical trials market: Porter's five forces analysis
  • Fig. 15 Rare disease clinical trials market: PESTLE analysis
  • Fig. 16 Rare disease clinical trials market: Phase segment dashboard
  • Fig. 17 Rare disease clinical trials market: Phase market share analysis, 2024 & 2030
  • Fig. 18 Phase I market, 2018 - 2030 (USD Billion)
  • Fig. 19 Phase II market, 2018 - 2030 (USD Billion)
  • Fig. 20 Phase III market, 2018 - 2030 (USD Billion)
  • Fig. 21 Phase IV market, 2018 - 2030 (USD Billion)
  • Fig. 22 Rare disease clinical trials market: Therapeutic area segment dashboard
  • Fig. 23 Rare disease clinical trials market: Therapeutic area market share analysis, 2024 & 2030
  • Fig. 24 Oncology market, 2018 - 2030 (USD Billion)
  • Fig. 25 Cardiovascular disorders market, 2018 - 2030 (USD Billion)
  • Fig. 26 Neurological disorders market, 2018 - 2030 (USD Billion)
  • Fig. 27 Infectious disease market, 2018 - 2030 (USD Billion)
  • Fig. 28 Genetic disorders market, 2018 - 2030 (USD Billion)
  • Fig. 29 Autoimmune and inflammation market, 2018 - 2030 (USD Billion)
  • Fig. 30 Hematologic disorders market, 2018 - 2030 (USD Billion)
  • Fig. 31 Musculoskeletal disorders market, 2018 - 2030 (USD Billion)
  • Fig. 32 Others market, 2018 - 2030 (USD Billion)
  • Fig. 33 Rare disease clinical trials market: Sponsor segment dashboard
  • Fig. 34 Rare disease clinical trials market: Sponsor market share analysis, 2024 & 2030
  • Fig. 35 Pharmaceutical & biopharmaceutical companies market, 2018 - 2030 (USD Billion)
  • Fig. 36 Non-profit organizations market, 2018 - 2030 (USD Billion)
  • Fig. 37 Other market, 2018 - 2030 (USD Billion)
  • Fig. 38 Rare disease clinical trials market revenue, by region
  • Fig. 39 Regional marketplace: Key takeaways
  • Fig. 40 North America rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 41 U.S. country dynamics
  • Fig. 42 U.S. rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 43 Canada country dynamics
  • Fig. 44 Canada rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 45 Mexico country dynamics
  • Fig. 46 Mexico rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 47 Europe rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 48 UK country dynamics
  • Fig. 49 UK rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 50 Germany country dynamics
  • Fig. 51 Germany rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 52 France country dynamics
  • Fig. 53 France rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 54 Italy country dynamics
  • Fig. 55 Italy rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 56 Spain country dynamics
  • Fig. 57 Spain rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 58 Denmark country dynamics
  • Fig. 59 Denmark rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 60 Sweden country dynamics
  • Fig. 61 Sweden rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 62 Norway country dynamics
  • Fig. 63 Norway rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 64 Asia Pacific rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 65 Japan country dynamics
  • Fig. 66 Japan rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 67 China country dynamics
  • Fig. 68 China rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 69 India country dynamics
  • Fig. 70 India rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 71 South Korea country dynamics
  • Fig. 72 South Korea rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 73 Australia country dynamics
  • Fig. 74 Australia rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 75 Thailand country dynamics
  • Fig. 76 Thailand rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 77 Latin America rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 78 Brazil country dynamics
  • Fig. 79 Brazil rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 80 Argentina country dynamics
  • Fig. 81 Argentina rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 82 MEA rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 83 South Africa country dynamics
  • Fig. 84 South Africa rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 85 Saudi Arabia country dynamics
  • Fig. 86 Saudi Arabia rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 87 UAE country dynamics
  • Fig. 88 UAE rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 89 Kuwait country dynamics
  • Fig. 90 Kuwait rare disease clinical trials market, 2018 - 2030 (USD Billion)
  • Fig. 91 Company categorization
  • Fig. 92 Company market position analysis
  • Fig. 93 Strategic framework